GILEAD SCIENCES RESEARCH SCHOLARS PROGRAM IN CARDIOVASCULAR DISEASE

Supporting innovative scientific research that will advance knowledge in the field of cardiovascular disease

GILEAD
Advancing Therapeutics.
Improving Lives.

http://researchscholars.gilead.com

GILEAD
Advancing Therapeutics.
Improving Lives.

GILEAD SCIENCES RESEARCH SCHOLARS PROGRAM IN CARDIOVASCULAR DISEASE

TABLE OF CONTENTS

MISSION STATEMENT

The mission of the Gilead Sciences Research Scholars Program in Cardiovascular Disease is to support innovative scientific research that will advance knowledge in the field of cardiovascular disease. Gilead Sciences, Inc. expects that the research supported by these awards will enhance understanding of cardiovascular disease and develop the careers of early stage investigators.

PROGRAM OVERVIEW

The Program provides financial support to 3 junior faculty researchers for a 2-year period. Each award is funded up to $130,000 (inclusive of any indirect costs), to be paid in annual installments of up to $65,000 per year for 2 years. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair.

Recipients of these competitive awards will be selected by the Committee, comprised of leaders in the field of cardiovascular disease. The Committee will review complete applications and select research proposals based on their scientific merit, feasibility, and innovation. Announcement of Award Recipients will be made at an awards dinner hosted by the Committee and senior representatives from Gilead Sciences.

Applicants must meet the eligibility criteria in order to be considered for an award. Refer to the Eligibility section on page 4.

SCIENTIFIC FOCUS

The Program is designed to support basic and clinical research in the field of cardiovascular disease.

Awards granted under the Gilead Sciences Research Scholars Program in Cardiovascular Disease may not be duplicative of funding from other government, non-governmental, or industry sources. Applicants seeking an Award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

Proposals are reviewed by an independent Scientific Review Committee (no Commercial involvement in review and selection, i.e., Marketing, Sales and Commercial Strategy), and are reviewed based upon the criteria outlined in this brochure.

SCIENTIFIC REVIEW COMMITTEE

Applications will be reviewed by an independent academic Committee comprised of internationally recognized experts in basic and clinical research in the field of cardiovascular medicine.

Chair:

Joseph A. Hill, MD, PhD
James T. Willerson MD, Distinguished Chair
in Cardiovascular Diseases
Professor of Medicine and Molecular Biology
Chief, Division of Cardiology
UT Southwestern Medical Center
Dallas, TX

Review Committee:

Peter Ganz, MD
Maurice Eliaser Distinguished
Professor of Medicine
University of California, San Francisco
Chief, Division of Cardiology
San Francisco General Hospital
San Francisco, CA

Robert E. Gerszten, MD
Herman Dana Professor of Medicine
Harvard Medical School
Chief, Cardiovascular Medicine
Beth Israel Deaconess Medical School
Boston, MA

Christopher Granger, MD
Professor of Medicine
Duke University
Director, Cardiac Intensive Care Unit
Duke University Medical Center
Durham, NC

Elizabeth McNally, MD, PhD
Professor and Director
Center for Genetic Medicine
Elizabeth J. Ward Chair
Northwestern University
Feinberg School of Medicine
Chicago, IL

Jean E. Schaffer, MD
Virginia Minnich Distinguished
Professor of Medicine
Director, Diabetic Cardiovascular
Disease Center and Diabetes
Research Center
Washington University
School of Medicine
St. Louis, MO

Gordon F. Tomaselli, MD
Michel Mirowski Professor of Cardiology
Professor of Medicine and
Molecular Medicine
Chief, Division of Cardiology
Johns Hopkins University
Baltimore, MD

ELIGIBILITY

This award is intended for junior faculty who are in the early stages of their career; specifically, the Applicant may be the recipient of a career development (K) award or other mentored research award, but not a funded RO1 grant or equivalent at time of application.

Applicants must meet the following requirements:

- Hold an MD, DO, PhD, or equivalent degree at time of award
- Be within 5 years of an initial faculty appointment
- Be associated with an academic research institution in the United States at the time of application
- Have a strong career interest in cardiovascular disease
- Be able to devote at least 50% of professional time to research (versus administrative, patient care, or teaching responsibilities)
- Be able to complete the proposed research within the 2-year award period

Citizenship

An Applicant must be a citizen or permanent resident of the United States or hold a temporary nonimmigrant visa. This visa must be valid for the two-year award period (January 2, 2017 – December 31, 2018).

CRITERIA FOR SELECTION

In their evaluation, the Committee will consider the following criteria:

Criterion 1: Evaluation of the Applicant

- Potential for a career in cardiovascular disease-related research
- Academic record
- Prior research experience and/or publications
- Clearly written presentation supporting the research need

Criterion 2: Scientific Environment and Institutional Support

- Letter of Support from the Division Chief or Department Chair which confirms that the proposed scientific environment will contribute to the probability of success and that the institution is willing and able to commit sufficient resources for the conduct of the research
- Does the proposed scientific environment contribute to the probability of success and is the institution willing and able to commit the resources necessary for the Applicant to complete the proposed research, including sufficient protected time?

Criterion 3: Evaluation of the Proposal

- *Innovation and Significance*: Is the proposed research new and original and does it address an important question/issue related to cardiovascular disease? Will this study have an effect on concepts, methods, and/or technologies related to cardiovascular disease research?
- *Approach*: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, well-reasoned, feasible (as determined by preliminary data or the expertise available), and appropriate to the aims of the project? Does the Applicant acknowledge potential problem areas and consider alternative tactics?
- *Feasibility*: Can the project, as described in the submitted proposal and budget, be accomplished within the timeframe of the award?

APPLICATION INFORMATION

Submission Deadline: Friday, July 8, 2016, Midnight, Eastern Daylight Time
No applications will be accepted after this date.

Applications must be completed online and submitted electronically with the required Supplementary Materials to http://researchscholars.gilead.com

If you have any questions, or require further information, please contact:
Research Scholars Program Coordinator
Telephone: 646-674-1820
E-mail: cvdresearchscholars@contacthmc.com

Application

Applicants must complete the online Application Form (all fields must be completed or Applicant will not be able to submit) and include the following Supplementary Materials as specified:

- Research Abstract
- Research Proposal
- Applicant's NIH biosketch, inclusive of publications, if applicable
- Letter of Support from the Division Chief or Department Chair which confirms that the proposed scientific environment will contribute to the probability of success and that the institution is willing and able to commit sufficient resources for the conduct of the research, including sufficient protected time
- Bibliography of relevant references (maximum of 20)
- Detailed budget and completed budget summary

- Acknowledgement of Indirect Costs Limitation, using the template provided on the Program website
- Certification of Faculty Appointment, using the template provided on the Program website
- Current or Pending Funding, using the template provided on the Program website

Please note: Feedback for specific proposals will not be provided.

GUIDELINES FOR THE RESEARCH PROPOSAL

The Research Proposal should be a clear and concise presentation of the Applicant's proposed research. It is highly recommended that the Applicant's Division Chief or Department Chair review the proposal before it is submitted.

The Proposal must include:

Research Abstract

Provide an abstract of no more than 325 words outlining the Applicant's proposed research.

Research Proposal

Proposal must be single-spaced (using 11 point Arial font or larger) and limited to 5 pages total, not including the bibliography or budget. At least one-half inch margins (top, bottom, left, and right) should be used for all pages. No information should be written in the margins. Applications with proposals over 5 pages will not be accepted. Please add your bibliography to your proposal but do not include those pages in the 5-page limitation.

The proposal must include:

1. Title of the proposed research
2. Description of research objectives, including relevant literature, specific aims, study design, methodology, data, and projected results
3. Discussion of the innovation of the proposed research to cardiovascular disease
4. Description of analytical methods (figures and tables should be included in the body of the text, where applicable)
5. Description of potential research challenges and possible approaches for overcoming them
6. Description of relevant past work by the Applicant, including joint collaborations and references

BUDGET GUIDELINES

Indirect Costs:

- In an effort to maximize the research benefit of the Award, the Program encourages that every effort be made to minimize the utilization of the Award to cover indirect costs. Indirect costs may not exceed 10% of the Award value, and are included as part of the budget, not as an addition to the value of the Award

Salaries:

- The Applicant may allocate up to $50,000 per year in salary and fringe benefits support for the researcher, technician, and/or collaborator (which may or may not include a post-doctoral fellow or student)

Supplies:

- Supplies such as disposables, chemicals, reagent kits, animals, etc, may be included
- Equipment purchases with a single item value of greater than $2,500 may not be included

Travel:

- Up to $1,500 per year for Applicant's travel to a scientific meeting for presentation of data may be included

If the research project includes investigations on human subjects, a copy of the submission to the institutional review board (IRB) must be submitted prior to Award. Award will be contingent upon IRB approval.

If the research project involves laboratory animals, researcher must certify that he/she will comply with all laws and regulations pertaining to care and use of animals in research prior to Award.

PROGRAM TIMELINE

The timeline, from application submission to award disbursement, is below:

Application Deadline	Friday, July 8, 2016, Midnight, Eastern Daylight Time
Applicant Notification	Friday, October 7, 2016
Award Disbursement	January 2, 2017

INQUIRIES/CONTACT INFORMATION

For general inquires about the Research Scholars Program, please call or e-mail:

Gilead Sciences Research Scholars Program in Cardiovascular Disease
Attn: Research Scholars Program Coordinator
Telephone: 646-674-1820
E-mail: cvdresearchscholars@contacthmc.com

FUNDING CONSIDERATIONS

If you are selected as an Award Recipient, you and your institution must agree to the following items, including, but not limited to:

■ Exclusive Use of Funding

In an effort to maximize the research benefit of the Award, the Program encourages that every effort be made to minimize the utilization of the Award to cover indirect costs. Indirect costs may not exceed 10% of the Award value. Funding is contingent upon Committee approval of the itemized budget.

■ Use of Gilead Product

Proposals utilizing Gilead product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through our online portal: http://www.gilead.com/research/investigator-sponsored

■ Progress Reports

Submission of research progress and financial accounting reports for review by the Committee are required annually. Funding for the second year is contingent upon Committee Chair approval of the research progress report. It is the expectation that individual Award Recipients will be able to provide follow-up through the years about their current position.

■ Intellectual Property

The host institution shall retain ownership of inventions made by the institution and investigator during the conduct of the research.

■ Change of Institution or Discontinuation

The Research Scholars Program Coordinator must be notified immediately if the Award Recipient leaves the host institution or discontinues the research funded by the Program. In the event Award Recipient moves to another institution, the award may be transferred at the sole discretion of the Committee. The new host institution must also agree to accept the terms and conditions of the existing award. In the event the host institution or Award Recipient is unable to complete the research or desires to discontinue the research before its completion, institution will be required to return all unexpended funds and any remaining award will be terminated.

Award Recipients and their institutions will be required to enter into a written grant agreement with Gilead Sciences, Inc. prior to receipt of funding.

PROGRAM AWARD RECIPIENTS

2010 Recipients

Kevin Croce, MD, PhD
Brigham and Women's Hospital
"Microparticles in the Pathobiology of Atherothrombosis"

Thomas Hund, PhD
University of Iowa Carver College of Medicine at time of award;
Transferred to Ohio State University
"CaMK/1-Dependent Regulation of Voltage-Gated Na+ Channels in Health and Disease"

Hesham Sadek, MD, PhD
UT Southwestern Medical Center
"Glycolytic Cardiac Stem Cells"

2011 Recipients

Reza Ardehali, MD, PhD
Stanford University at time of award; Transferred to UCLA
"Prospective Isolation of Human Embryonic Stem Cell-derived Cardiovascular Progenitors without the Risk of Teratoma Formation"

Nicholas Leeper, MD
Stanford University
"The Role of CDKN2B in Atherosclerotic Plaque Vulnerability"

Tracy Wang, MD, PhD
Duke Clinical Research Institute/Duke University
"Age-associated Heterogeneity in Bleeding and Platelet Response to Clopidogrel"

PROGRAM AWARD RECIPIENTS

2012 Recipients

Brian Lindman, MD
Washington University School of Medicine
"Galectin-3 as a Mediator of Cardiac Fibrosis and Diastolic Dysfunction in the Pressure Overloaded Diabetic Heart"

Marvin Nieman, PhD
Case Western Reserve University
"Biophysical Analysis of Protease Activated Receptor 1 (PAR1) and PAR4"

Mintu Turakhia, MD
Palo Alto Institute for Research and Education, Inc.
"Comparative Effectiveness and Safety of Atrial Fibrillation Therapies in Chronic Kidney Disease"

2013 Recipients

John Chorba, MD
University of California, San Francisco
"Targeted Inhibition of PCSK9 via a Deeper Understanding of the Dual Roles of the Active Site"

Kevin Hill, MD, MS
Duke University Medical Center
"Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Children with Single Ventricle Heart Defects"

Lisa Wilsbacher, MD,PhD
University of California, San Francisco at time of award;
Transferred to Northwestern University
"Sphingosine-1-Phosphate Receptor-1 in Mammalian Sarcomere Assembly, Cardiac Development, and Sarcomere Maintenance"

PROGRAM AWARD RECIPIENTS

2014 Recipients

Jobert G. Barin, PhD
Johns Hopkins University School of Medicine
"Innate Lymphoid Cells Couple the Commensal Microbiota to Cardiac Inflammation and Remodeling"

Meena Madhur, MD, PhD
Vanderbilt University School of Medicine
"Dissecting Immune Mechanisms of Aortic Dissection: Development of a Novel Mouse Model of Rapid Aortic Dissection and Rupture via Loss of the Adaptor Molecule LNK/SH283"

Benjamin Olenchock, MD, PhD
Brigham and Women's Hospital
"EglN Dioxygenases Mediate Remote Cardiac Ischemic Protection via Regulation of Tryptophan Metabolism"

2015 Recipients

Angeliki Asimaki, PhD
Harvard Medical School/Beth Israel Deaconess Medical Center
"Mechanisms of Pathogenesis of Arrhythmogenic Cardiomyopathy (ACM)"

Young-Jae Nam, MD, PhD
Vanderbilt University School of Medicine
"Exploring the Rules Underlying Cardiac Fate Reprogramming by Defined Factors"

Matthew Steinhauser, MD
Harvard Medical School/Brigham and Women's Hospital
"The Role of Adipocyte Progenitor Quiescence in Systemic Insulin Resistance"

http://researchscholars.gilead.com